Numinus Wellness Inc.

The trial evaluates Numinus' first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its... Read More...

Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, commends Health Canada's leadership for amending th... Read More...

Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients VANCOUVER, BC, Nov. 29, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compo... Read More...

VANCOUVER, BC, Nov. 25, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions that Stacey Wallin, former Chief Strategy Officer, is no longer with t... Read More...

Numinus will manage two new clinics in Montreal and Vancouver to host trials. VANCOUVER, BC, Nov. 10, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has secured two new Canadian psychedelic clinics that will host the Canadian sites of the MAPS Publi... Read More...

Additional lab facility and federal licence application add expanded contract services to portfolio VANCOUVER, BC, Oct. 8, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce the expansion of its psychedelics research facility with an additional lab and applicat... Read More...

VANCOUVER, BC, June 18, 2021 -  Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received approval to graduate  to Tier 1 Issuer status on the TSX Venture Exchange (the "TSXV"), effective ... Read More...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, Jan. 14, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic... Read More...

Acquisition of industry-leading instrument by Thermo Fisher Scientific will significantly advance psychedelic research and accelerate third-party standardized testing capabilities VANCOUVER, BC, Jan. 13, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing an... Read More...

Proceeds add to recently executed warrants and options of $8.9 million /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, Dec. 29, 2020 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing... Read More...

 First-of-its-kind policy amendment will allow legal access to evidence-based treatments to those in need before formal drug approval  VANCOUVER, BC, Dec. 11, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, access... Read More...

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./VANCOUVER, BC, Dec. 7, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and suppo... Read More...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.VANCOUVER, BC, Dec. 7, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and support... Read More...

Numinus Bioscience's developments include harvesting its first flush of Psilocybe mushrooms at its Health Canada licensed facility.VANCOUVER, BC, Oct. 22, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use ... Read More...

Advisors, including human performance expert Jamie Wheal and mental health advocate Ben Nemtin, join Numinus to help guide and inform company leadership VANCOUVER, BC, Oct. 14, 2020 - Recognized and respected leaders from technology, pharmacology, and health have joined Numinus Wellness Inc. ("Numinus") (TSXV: NUMI) as members of the Comp... Read More...

Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies VANCOUVER, BC, Sept. 24, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, ac... Read More...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, Sept. 18, 2020 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic... Read More...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, Sept. 10, 2020 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), is pleased to announce that it has closed its previously announced short form prospectus offering, on a best efforts basis, including the exercise o... Read More...

/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/VANCOUVER, BC, Sept. 3, 2020 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted ther... Read More...

Advisors including Dr. Gabor Maté and Zach Walsh bring training and expertise in psychedelic-assisted therapy and mental health treatment VANCOUVER, BC , June 24, 2020 - Numinus Wellness Inc. ("Numinus") (NUMI.V) is pleased to announce its Clinical Advisory Council, chaired by Numinus Chief Medical Officer Dr. Evan Wood . Leveraging the e... Read More...

Numinus becomes first publicly traded company in Canada approved to conduct research of this kind under a Health Canada licence VANCOUVER, BC, June 11, 2020 - Numinus Wellness Inc. (TSX-V:NUMI) ("Numinus") has received Health Canada approval to amend the Company's existing Licence under the Controlled Drug and Substances Act to allow Numi... Read More...